Effective downregulation of BCR-ABL tumorigenicity by RNA targeted CRISPR-Cas13a

Abstract

6CML is a clonal myeloproliferative disorder of pluripotent stem cells driven by a reciprocal 1 7 translocation between chromosome 9 and 22, forming a BCR-ABL fusion gene. Tyrosine 1 8 kinase inhibitor drugs like imatinib are mainstay of treatment and cases resistant to these 1 9 3 1 in Hematological neoplasms like CML and should pave way for further research in this 3 2 direction.